OPT-80

fidaxomicin · Optimer Pharmaceuticals LLC (a subsidiary of Merck & Co.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OPT-80, covering 2017-03-27 to 2017-03-27. Get the full timeline:

Most recent: Clinical Trial Update: OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD) [Phase 2]